Scientists at The University of Nottingham have been searching for polymers on which human pluripotent stem cells can be grown and differentiated in vast numbers - billions at a time.
"The possibilities for regenerative medicine are still being researched in the form of clinical trials. What we are doing here is paving the way for the manufacture of stem cells in large numbers when those therapies are proved to be safe and effective," said Morgan Alexander, Professor of Biomedical Surfaces in the School of Pharmacy.
"The field of regenerative medicine has snowballed in the last five years and over the coming five years a lot more patients will be receiving stem cell treatments," said Chris Denning, Professor of Stem Cell Biology in the School of Medicine.
"Clinical trials are still in the very early stages. However, with this kind of product, if we can get it commercialised and validated by the regulators it could be helping patients in two to three years," Denning said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
